Latest News

  • Follow the Money: Sepsis Diagnostic Test, Expanding Cardiovascular Disease Info, Oncology, Peptide Therapeutics, CRISPR

    Diagnostics World | Cytovale will bring its rapid sepsis diagnosis test to more hospital emergency departments (ED) and health systems in the United States; Elucid intends to expand its commercialization efforts to provide physicians and patients with critical information to combat heart disease; Flashpoint Therapeutics to advance its programs on Oncology, Peptide Therapeutics, and CRISPR; more.

    Nov 30, 2023
  • Illumina Partners With Veracyte; Boston Scientific Corporation Acquires Relievant Medsystems; Oxford Nanopore Collaborates With Fabric Genomics

    Diagnostics World | Illumina enters a multi-year agreement with Veracyte to develop and offer some of its high-performing molecular tests as decentralized in vitro diagnostic (IVD) tests on Illumina’s NextSeq 550Dx next-generation sequencing (NGS) instrument; Boston Scientific Corporation acquires Relievant Medsystems to add to chronic pain portfolio; Oxford Nanopore Technologies and Fabric Genomics collaborate to develop a software solution analysis and clinical reporting of rich genomic data for faster insights to support rapid disease characterization of babies and children with genetic disorders in acute settings; more.

    Nov 29, 2023
  • AI-Based Platform For Detecting AFib Put To The Test In VA Facilities

    Diagnostics World | Investigators at Cedars-Sinai Medical Center are looking to minimize the biases in the data used by artificial intelligence (AI) algorithms, most recently a deep learning model trained on nearly a million electrocardiograms (ECGs) to identify people with abnormal heart rhythms.

    Nov 28, 2023
  • For Equitable CF Screening, We Should Expand Our Definition of Pathogenic Variants

    Diagnostics World | Cystic fibrosis (CF) is one of the few genetic disorders to be considered both serious and common enough to merit universal carrier or prenatal screening. Unfortunately, though, current testing approaches are caught between evolution and revolution even as they continue to produce suboptimal results for people of non-European ancestry.

    Nov 21, 2023